Updates

Date: 05th August, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Outcome of Board Meeting In reference to our letter dated 26th July, 2026, we wish to inform you that the Board of Directors at their meeting held today i.e., on 05th August, 2026, have inter-alia, approved the following: 1. Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2026. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2026, accompanied by Limited Review Report thereon by the Statutory Auditors of the Company as Annexure A & Annexure B respectively. 2. Took Note of the Progress of the Company's First Pharmaceutical Formulation Plant at Jadcherla, Hyderabad: The Board of Directors took note of the progress of the Company's first pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad, as apprised by the Managing Director. The Board noted that the Company has successfully commenced commercial production at the facility with its initial two products, Paracetamol Tablets 500mg and Piroxicam Capsules 20mg, marking the beginning of commercial manufacturing operations. The Board further noted that the Company has received manufacturing product permissions for an additional 29 products, taking the total approved commercial product portfolio to 31 products. Raw materials and key input materials for these products have started arriving at the facility, and commercial production will be initiated progressively in line with market requirements. The Company continues to pursue approvals for additional products and will further expand its manufacturing product portfolio in a phased manner. The Board was also apprised that the WHO-GMP audit of the facility was conducted during July 2026 through a joint inspection by CDSCO and the State FDA. The audit observation report has been received, and the Company has submitted its CAPA response to the regulatory authorities for their review. The Company is on track for obtaining WHO-GMP certification which will further strengthen its manufacturing credentials and support future growth opportunities. The Board expressed satisfaction with the progress achieved and noted that the Company continues to make steady progress in expanding its manufacturing operations and product portfolio, reinforcing its long-term growth strategy. The Board meeting commenced at 12.40 P.M. (IST) and concluded at 1.30 P.M. (IST). The aforesaid information is also being hosted on the Company’s website at www.balaxipharma.in. This is for your information and records. Thanking You. Yours faithfully, For Balaxi Pharmaceuticals Limited Aman Purohit (Company Secretary and Compliance Officer) ICSI Membership No.: A59345 Encl: As above ANNEXURE - A Balaxi Pharmaceuticals Limited 2nd Floor, MAPS Towers, Plot no. -109, Road no. 81, Jubilee Hills, Phase lll, 1l yderabad-500096, Telangana CIN: L25191TG1942PLC121598 Unaudited Standalone Financial Results for the Quarter Ended 30th June, 2026 Rs.in lakhs Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (UnauditP<I) (Audited) (Unaudited) (Audited) Income Revenue from operations 1,558.37 2,023.96 1,670.82 8,085.11 Other income 91.62 336.69 46.22 966.72 Total Income 1,649.99 2,360.65 1,717.04 9,051.83 Expenses Cost of Goods Sold 1,336.27 1,741.63 1,-117.59 6,911.42 Emplovee benefit expense 186.61 229.46 131.35 599.84 Finance cost 4-1.65 70.72 63.10 269.63 Depreciation and amortisation expense 59.20 31.29 11.28 70.21 Administrative exoenses 134.91 245.99 67.89 497.47 Total Expenses 1,761.64 2,319.29 1,691.21 8,348.56 Profit/(loss) before tax and other comprehensive income (111.65) 41.35 25.83 703.28 Tax expenses Current tax - (20.96) 8.12 145.12 Deferred tax 13.67 46.51 n.78) 43.-17 Net Profit/Hoss) for the period (125.32] 15.80 19.49 514.68 Other comprehensive income A (i) Items that will not be ~eclassified to profit or loss in subsequent period Re-measured gains on defined benefit plans (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total comprehensive income for the year (125.32) 15.80 19.49 514.68 Paid up equity share capital -Face value of Rs.2 each 1,104.15 1,104.15 1,104.15 1,104.15 Other Equity Earnings Per Share (EPS) (EPS for the quarter is not annualised) -Basic /Amount in Rs.) <0.23) 0.03 0.0-1 0.93 -Diluted I Amount in Rs.) (0.23) 0.03 0.04 0.93 Notes: 1. The un-audited Financial Results for the Quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 5th August, 2026. The Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. 2. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification. 3. The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1 )(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company. ~a~CEU1 ~, For and on b alf of Board of Directors I; "'{ " < of Balaxi P maceuticals Limited Hyderabad ~ ) +,&.; " ?t,,8 * 0:'>' Y ✓ sh· Maheshwari Place: Hyderabad .;,1V1anaging Director Date: 5th August, 2026 DIN: 01575984 P. MURALI & CO., Tel. : (91-40) 2332 6666, 2331 2554 CHARTERED ACCOUNTANTS . (91-40) 2339 3967, 6-3-655/2/3, SOMAJIGUDA (91-40) 2332 2119, 2331 7032 HYDERABAD - 500 082. T.G, INDIA Email : pmurali.co@gmail.com pmurali.tax@gmail.com info@pmurali.com Website : www.pmurali.com Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review report to The Board of Directors Balaxi Pharmaceuticals Limited We have reviewed the accompanying statement of unaudited standalone financial results of BALAXI PHARMACEUTICALS LIMITED (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries,. primarily of pers [Showing first 8,000 characters — download PDF for full document]